A Missense Variant in TP53 Could Be a Genetic Biomarker Associated with Bone Tissue Alterations

Metabolic bone diseases cover a broad spectrum of disorders that share alterations in bone metabolism that lead to a defective skeleton, which is associated with increasing morbidity, disability, and mortality. There is a close connection between the etiology of metabolic bone diseases and genetic f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2024-02, Vol.25 (3), p.1395
Hauptverfasser: Usategui-Martín, Ricardo, Galindo-Cabello, Nadia, Pastor-Idoate, Salvador, Fernández-Gómez, José María, Del Real, Álvaro, Ferreño, Diego, Lapresa, Rebeca, Martín-Rodriguez, Francisco, Riancho, José A, Almeida, Ángeles, Pérez-Castrillón, José Luis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Metabolic bone diseases cover a broad spectrum of disorders that share alterations in bone metabolism that lead to a defective skeleton, which is associated with increasing morbidity, disability, and mortality. There is a close connection between the etiology of metabolic bone diseases and genetic factors, with being one of the genes associated therewith. The single nucleotide polymorphism (SNP) Arg72Pro of is a genetic factor associated with several pathologies, including cancer, stroke, and osteoporosis. Here, we aim to analyze the influence of the Arg72Pro SNP on bone mass in humanized Tp53 Arg72Pro knock-in mice. This work reports on the influence of the Arg72Pro polymorphism in bone microarchitecture, OPG expression, and apoptosis bone status. The results show that the proline variant of the TP53 Arg72Pro polymorphism (Pro72-p53) is associated with deteriorated bone tissue, lower OPG/RANK ratio, and lower apoptosis in bone tissue. In conclusion, the Arg72Pro polymorphism modulates bone microarchitecture and may be a genetic biomarker that can be used to identify individuals with an increased risk of suffering metabolic bone alterations.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25031395